Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2011 Results
Date:5/5/2011

ands)

201120102010Total cash and marketable securities

$
94,555$
98,037$
202,424(1) Unaudited

(2) Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses.OPERATIONAL HIGHLIGHTS   First quarter 2011 sales of Fanapt® were reported by Novartis to be $9.0 million.  Fanapt® prescriptions, as reported by IMS, reached 25,000 in the first quarter of 2011.

Novartis initiated a clinical study for the once a month injectable depot formulation of Fanapt® in April 2011.  This is a Phase I study that will evaluate the safety and pharmacokinetic profiles of two different long-acting formulations of Fanapt® in patients with schizophrenia.  A long-acting injectable formulation could offer a potential new option for patients with schizophrenia who might benefit from less frequent dosing compared to an oral medication.

Vanda expects to file for European regulatory approval of oral Fanapt® in the second half of 2011.  This continues the effort to expand the availability of Fanapt® to markets outside the U.S. and Canada.  

On March 31, 2011, Vanda announced plans to evaluate tasimelteon in Major Depressive Disorder.   There is considerable evidence that suggests circadian rhythm disturbances are important in the pathophysiology of mood disorders.  Treatment with tasimelteon would represent a novel and differentiated approach to assisting the millions of patients who suffer from the symptoms of major depression.  A Phase IIb/III clinical trial will examine safety and efficacy of tasimelteon versus placebo and is expected to begin during the second half of 2011.  The study will include an 8-week treatment period and an optional open-label extension.

Enrollment is ongoing in tasimelteon studies VP-VEC-162-3201 (efficacy) and VP-VEC-162-3202 (safety) in the treatment of N24HSWD in
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
6. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
7. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
8. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
9. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
10. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... trademark owners have been battling search engines and online ... that trigger online advertising. Two recent and conflicting rulings ... law to the new keyword technology can be a ... a recent court ruling on advertising triggered by the ...
... high gas costs and poor sport utility vehicle (SUV) ... at the University of Wisconsin-Madison has spent the last ... fuel-efficient SUVs in North America. The principles behind the ... incorporated into mass-production hybrid SUVs. , ,The effort is ...
... Wis. - Before Gov. Jim Doyle ... of stem cell research, a key Republican legislator had already ... projects. , ,The projects, which now are the subject of ... the Doyle Administration by State Sen. Ted Kanavas , ...
Cached Biology Technology:Keyword advertisers win some, lose some 2Keyword advertisers win some, lose some 3Keyword advertisers win some, lose some 4Keyword advertisers win some, lose some 5UW-Madison hybrid-vehicle team places second nationally 2GOP lawmaker faults Doyle for IT problems 2GOP lawmaker faults Doyle for IT problems 3
(Date:4/14/2014)... RICHLAND, Wash. Think of the pressure change you feel ... tall building. Imagine how you,d feel if that elevator carried ... Everest in the blink of an eye. , That,s ... the turbulent waters near a dam. For some, the change ... die or are seriously injured. , In an article in ...
(Date:4/14/2014)... collaborators have reconstructed the phylogeny and biological history for ... region of the Earth surrounding the equator. In-depth ... species new to science, each having previously been confused ... on this group began, Sturnira has grown ... were described in a new study, published online in ...
(Date:4/14/2014)... an animal stops to look around its environment, neuroscientists ... the birth of a memory. , Using lab ... neuroscience in the Zanvyl Krieger Mind/Brain Institute at Johns ... the rats frequently paused to inspect their environment with ... this behavior activated a place cell in their brain, ...
Breaking Biology News(10 mins):Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5Three new species of yellow-shouldered bats discovered in museum collections 2Three new species of yellow-shouldered bats discovered in museum collections 3Neuroscientists: Brain activity may mark the beginning of memories 2Neuroscientists: Brain activity may mark the beginning of memories 3
... years of exhaustive analysis led by a University of Alberta ... exploded from just a handful to more than 4,000. ... ailing patient looks at something like 10 to 20 chemicals," ... blood chemicals that doctors can potentially look at to diagnose ...
... 24, 2011 For a week in March, the permanent ... and other attractions becomes the world capital of science as ... 241st National Meeting & Exposition of the American Chemical Society ... world,s largest scientific society, and the sessions in balmy Anaheim ...
... identified a strain of probiotic bacteria that may be useful ... They report their findings in the February 2011 issue of ... H. pylori is considered one of the major risk ... ulcers," write the researchers. "Currently, antibiotic-based treatment for ...
Cached Biology News:Researcher lists more than 4,000 components of blood chemistry 2American Chemical Society National Meeting & Exposition, March 27-31, Anaheim, Calif. 2Probiotic identified to treat ulcers 2
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
...
Biology Products: